股腘动脉血运重建中血管内超声应用的趋势与结局:血管质量倡议研究
该回顾性队列研究利用血管质量倡议2016至2021年数据,分析股腘动脉腔内血运重建中血管内超声(IVUS)的使用趋势及与12个月结局的关联。IVUS使用率从0.6%升至8.2%,在门诊手术中心或办公室实验室增长最显著。倾向评分匹配后,IVUS与主要无截肢生存改善相关,但多变量分析显示IVUS并非独立相关因素,技术结局无差异。
要点
- IVUS在股腘动脉介入中的使用率从2016年0.6%增至2021年8.2%。
- 门诊手术中心或办公室实验室的IVUS使用率从4.4%增至43%至47%。
- 多变量分析中IVUS与12个月主要结局无独立关联,结局主要受CLTI、透析依赖和既往大截肢影响。
核心结论
- 股腘动脉介入中IVUS使用不断增长,在门诊手术中心和办公室实验室中快速普及。
- IVUS与12个月技术结局无关联;观察到主要无截肢生存改善,但多变量分析提示该发现可能受与IVUS使用高度相关的多因素混杂影响,即患者CLTI、透析依赖和既往大截肢患病率较低,基线主要截肢和死亡风险较低。
研究设计与样本
- 回顾性队列研究,使用血管质量倡议数据,纳入2016至2021年接受指数性股腘动脉腔内血运重建的患者。
- 患者按介入期间是否使用IVUS评估股腘动脉段分为无IVUS组和IVUS组,基于术前人口学和疾病严重程度指标进行倾向评分匹配。
主要发现
- IVUS使用率从2016年0.6%稳步增至2021年8.2%;在门诊手术中心或办公室实验室环境中增长最显著,从4.4%增至43%至47%。
- 未匹配队列中,使用IVUS的患者多种心血管合并症(如充血性心力衰竭、高血压、糖尿病和透析依赖)患病率较低,更多表现为跛行,较少表现为慢性肢体威胁性缺血(CLTI)。
- 术中IVUS更常用于复杂股腘动脉病变(Transatlantic Intersociety分级D vs A),并更常与支架置入和/或斑块旋切术联合使用。
- IVUS与12个月主要无截肢生存改善相关,但无再干预生存和主要通畅生存相似。
- 多变量分析中IVUS与任何主要结局均无独立关联;所有结局主要受CLTI、透析依赖和既往大截肢状态影响;技术结局(即无再干预生存和主要通畅生存丧失)进一步受病变复杂性(Transatlantic Intersociety分级D vs A病变更差)和治疗环境(门诊手术中心或办公室实验室环境与无再干预生存和主要通畅生存丧失风险增加相关)驱动。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Intravascular ultrasound (IVUS) use in lower extremity interventions is growing in popularity owing to its imaging in the axial plane, superior detail in imaging lesion characteristics, and its enhanced ability to delineate lesion severity and extent compared with catheter angiograms. However, there are conflicting data regarding whether IVUS affects outcomes. The purpose of this study was to assess the effect associated with IVUS implementation in femoropopliteal interventions. METHODS: This retrospective cohort study used Vascular Quality Initiative data. Patients undergoing an index endovascular femoropopliteal revascularization from 2016 to 2021 were included. Patients were differentiated by whether or not IVUS was used to assess the femoropopliteal segment during intervention (no IVUS, IVUS). Propensity score matching, based on preoperative demographics and measures of disease severity was used. Primary outcomes were major amputation-free survival (AFS), femoropopliteal reintervention-free survival (RFS), and primarily patent survival (PPS) at 12 months. RESULTS: IVUS use grew steadily throughout the study period, comprising 0.6% of interventions in 2016 and increasing to 8.2% of interventions by 2021; growth was most dramatic in ambulatory surgical center or office-based laboratory settings where IVUS use grew from 4.4% to 43% to 47% of interventions. In unmatched cohorts, patients receiving interventions using IVUS tended to have lower prevalence of multiple cardiovascular comorbidities (eg, congestive heart failure, hypertension, diabetes, and dialysis dependence) and presented more often with claudication and less often with chronic limb-threatening ischemia (CLTI). Intraoperatively, IVUS was used more often in complex femoropopliteal lesions (Transatlantic Intersociety grade D vs A), and more often in conjunction with stenting and/or atherectomy. IVUS use was associated with improved AFS, but similar RFS and PPS at 12 months. However, in multivariable analysis IVUS was not associated with any of the primary outcomes independently; rather, all outcomes were influenced primarily by CLTI, dialysis dependence, and prior major amputation status; technical outcomes (ie, RFS and PPS loss) were further driven by complexity of lesion (worse in Transatlantic Intersociety grade D vs A lesions) and treatment setting (ie, ambulatory surgical center or office-based laboratory setting associated with increased hazard for RFS and PPS loss). CONCLUSIONS: IVUS implementation in femoropopliteal interventions is growing, with rapid adoption among interventions in ambulatory surgical centers and office-based laboratories. IVUS was not associated with an effect on technical outcomes at 12 months; improvement in major AFS was observed; however, multivariable analysis suggests this finding may be an effect of confounding by multiple factors highly associated with IVUS use, namely, in patients with lower prevalence of CLTI, dialysis dependence, and prior major amputations, thus conveying baseline lower risk for major amputation and death.
引用
- Smith JA, Yang L, Chen L, et al. Trends and outcomes associated with intravascular ultrasound use during femoropopliteal revascularization in the Vascular Quality Initiative. J Vasc Surg. 2023. PMID: 36944390. doi:10.1016/j.jvs.2023.03.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。